1. FGFR4 Arg388 Is Correlated with Poor Survival in Resected Colon Cancer Promoting Epithelial to Mesenchymal Transition
    Sang Hee Cho et al, 2017, Cancer Res Treat CrossRef
  2. Selective FGFR inhibitor BGJ398 inhibits phosphorylation of AKT and STAT3 and induces cytotoxicity in sphere-cultured ovarian cancer cells
    Hwa Jun Cha et al, 2017 CrossRef
  3. The Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics
    Jason N. Rosenbaum et al, 2017, The American Journal of Pathology CrossRef
  4. FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ERα-Positive Breast Cancer Cells
    Lukasz Turczyk et al, 2017, Neoplasia CrossRef
  5. bFGF in tumor tissue independently prognosticates disease outcome of a natural course of invasive breast cancer
    Nataša Todorović-Raković et al, 2017, CBM CrossRef
  6. Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer
    Bernhard Englinger et al, 2017, J Exp Clin Cancer Res CrossRef
  7. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors
    Tomohiro Nishina et al, 2017, Invest New Drugs CrossRef
  8. Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
    Narayan Shivapurkar et al, 2017, Clin Trans Med CrossRef
  9. A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
    K P Papadopoulos et al, 2017, Br J Cancer CrossRef
  10. The integration of genomics testing and functional proteomics in the era of personalized medicine
    Masaru Katoh, 2017, Expert Review of Proteomics CrossRef
  11. Myeloid/lymphoid neoplasms with FGFR1 rearrangement
    Paolo Strati et al, 2017, Leukemia & Lymphoma CrossRef
  12. Collateral Damage Intended—Cancer-Associated Fibroblasts and Vasculature Are Potential Targets in Cancer Therapy
    Ana Cavaco et al, 2017, IJMS CrossRef
  13. Involvement of mitogen activated kinase kinase 7 intracellular signalling pathway in Sunitinib-induced cardiotoxicity
    Samantha Louise Cooper et al, 2017, Toxicology CrossRef
  14. Assessment of FGFR1 Overexpression and Over-Activity in Lung Cancer Cells: A Toolkit for Anti-FGFR1 Drug Screening
    Penghui HU et al, 2017, Human Gene Therapy Methods CrossRef
  15. Splice variants of porcine PPHLN1 encoding periphilin-1
    Knud Larsen et al, 2017, Gene Reports CrossRef
  16. Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer
    Katarzyna Starska et al, 2018, Cell Oncol. CrossRef
  17. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review).
    Masaru Katoh, 2017, Int J Oncol CrossRef
  18. Soluble interleukin-2 receptor as a factor associated with angiogenesis in gastric cancer
    Wen-Feng Yan et al, 2017 CrossRef
  19. Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis
    S J Welsh et al, 2018, Leukemia CrossRef
  20. Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping
    Yikai Wang et al, 2017, Bioorganic & Medicinal Chemistry Letters CrossRef
  21. QSAR and Structure-Based Docking Studies of Aryl Pyrido[2,3-d]pyrimidin-7(8H)-ones
    Jyoti Durgapal et al, 2018 CrossRef
  22. SNCA , a novel biomarker for Group 4 medulloblastomas, can inhibit tumor invasion and induce apoptosis
    Yong-Xiao Li et al, 2018, Cancer Sci CrossRef
  23. Therapeutics Targeting FGF Signaling Network in Human Diseases
    Masaru Katoh, 2016, Trends in Pharmacological Sciences CrossRef
  24. Prognostic importance of FGF2 and FGFR1 expression for patients affected by ameloblastoma
    Felipe Paiva Fonseca et al, 2018, J Oral Pathol Med CrossRef
  25. Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma
    Ayano Kabashima et al, 2018, Journal of Hepatology CrossRef
  26. Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas—differences in mutation profiles in epithelial-derived oropharyngeal neoplasms
    Stephan Bartels et al, 2018, Virchows Arch CrossRef
  27. Tumor microenvironment – Unknown niche with powerful therapeutic potential
    Tomasz Kolenda et al, 2018, Reports of Practical Oncology & Radiotherapy CrossRef
  28. Computational Simulation Studies on the Binding Selectivity of 1-(1H-Benzimidazol-5-yl)-5-aminopyrazoles in Complexes with FGFR1 and FGFR4
    You-Lu Pan et al, 2018, Molecules CrossRef
  29. Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors
    Manman Wei et al, 2018, European Journal of Medicinal Chemistry CrossRef
  30. Papillomavirus E2 protein is regulated by specific fibroblast growth factor receptors
    Marsha DeSmet et al, 2018, Virology CrossRef
  31. Klotho negatively regulated aerobic glycolysis in colorectal cancer via ERK/HIF1α axis
    Qingguo Li et al, 2018, Cell Commun Signal CrossRef
  32. Future applications of FGF/FGFR inhibitors in cancer
    Gaia Cristina Ghedini et al, 2018, Expert Review of Anticancer Therapy CrossRef
  33. Inferring Novel Tumor Suppressor Genes with a Protein-Protein Interaction Network and Network Diffusion Algorithms
    Lei Chen et al, 2018, Molecular Therapy - Methods & Clinical Development CrossRef
  34. Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer
    Navid Sobhani et al, 2018, Cells CrossRef
  35. Recent developments and advances of FGFR as a potential target in cancer
    Wen-Jun Xue et al, 2018, Future Medicinal Chemistry CrossRef
  36. Novel pyrrole derivatives bearing sulfonamide groups: Synthesis in vitro cytotoxicity evaluation, molecular docking and DFT study
    Masoumeh Bavadi et al, 2017, Journal of Molecular Structure CrossRef
  37. Structural Alterations in Human Fibroblast Growth Factor Receptors in Carcinogenesis
    D. S. Mikhaylenko et al, 2018, Biochemistry Moscow CrossRef
  38. Non-mitogenic FGF2 protects cardiomyocytes from acute doxorubicin-induced toxicity independently of the protein kinase CK2/heme oxygenase-1 pathway
    Navid Koleini et al, 2018, Cell Tissue Res CrossRef
  39. Making way for suppressing the FGF19/FGFR4 axis in cancer
    Nestor Prieto-Dominguez et al, 2018, Future Medicinal Chemistry CrossRef
  40. Fibroblast growth factor receptors as treatment targets in clinical oncology
    Masaru Katoh, 2018, Nat Rev Clin Oncol CrossRef
  41. Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors
    Jing Cui et al, 2017, Bioorganic & Medicinal Chemistry Letters CrossRef
  42. Hepatic gene body hypermethylation is a shared epigenetic signature of murine longevity
    Oliver Hahn et al, 2018, PLoS Genet CrossRef
  43. Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting
    Brendan Farrell et al, 2018, Biochm. Soc. Trans. CrossRef
  44. Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics
    Bao T. Le et al, 2019, Molecular Therapy - Nucleic Acids CrossRef
  45. TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure
    Maria Kalyukina et al, 2019, ChemMedChem CrossRef
  46. The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial
    Charlotte M. Huijts et al, 2019, Cancer Immunol Immunother CrossRef
  47. Gene expression profiling in aggressive digital papillary adenocarcinoma sheds light on the architecture of a rare sweat gland carcinoma
    H.M. Surowy et al, 2019, Br J Dermatol CrossRef
  48. Chicken-Derived Humanized Antibody Targeting a Novel Epitope F2pep of Fibroblast Growth Factor Receptor 2: Potential Cancer Therapeutic Agent
    Keng-Chang Tsai et al, 2019, ACS Omega CrossRef
  49. Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry
    Burcu Dogan-Topal et al, 2019, Journal of Chromatography B CrossRef
  50. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
    R Condorelli et al, 2019, Ann Oncol CrossRef
  51. null
    Scott A. Hundahl et al, 2006 CrossRef
  52. Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models
    Sylvia Grünewald et al, 2019, Int. J. Cancer CrossRef
  53. GPER Mediates a Feedforward FGF2/FGFR1 Paracrine Activation Coupling CAFs to Cancer Cells Toward Breast Tumor Progression
    Maria Francesca Santolla et al, 2019, Cells CrossRef
  54. Silencing fibroblast growth factor 7 inhibits krypton laser‐induced choroidal neovascularization in a rat model
    Chao Zhang et al, 2019, J Cell Biochem CrossRef
  55. The evolving genomic landscape of urothelial carcinoma
    Alexander P. Glaser et al, 2017, Nat Rev Urol CrossRef
  56. Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers.
    Masaru Katoh, 2019, Clin Sci (Lond) CrossRef
  57. MiR‐16‐1‐3p and miR‐16‐2‐3p possess strong tumor suppressive and antimetastatic properties in osteosarcoma
    Vadim V. Maximov et al, 2019, Int. J. Cancer CrossRef
  58. Menstrual and Reproductive Factors, Exogenous Hormone Use, and Gastric Cancer Risk in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition
    Eric J. Duell et al, 2010 CrossRef
  59. MicroRNA-198 inhibits proliferation and induces apoptosis by directly suppressing FGFR1 in gastric cancer
    Junxia Gu et al, 2019, Biosci. Rep. CrossRef
  60. Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1
    Elizabeth A McNiel et al, 2017, Sig Transduct Target Ther CrossRef
  61. Critical role of the fibroblast growth factor signalling pathway in Ewing's sarcoma octamer‐binding transcription factor 4‐mediated cell proliferation and tumorigenesis
    Junghoon Kim et al, 2019, FEBS J CrossRef
  62. Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
    Shuyan Dai et al, 2019, Cells CrossRef
  63. Aberrant expression of intelectin-1 in gastric cancer: its relationship with clinicopathological features and prognosis
    Liduan Zheng et al, 2012, J Cancer Res Clin Oncol CrossRef
  64. Fibroblast Growth Factor Receptor Signaling in Skin Cancers
    null Czyz, 2019, Cells CrossRef
  65. MicroRNA-214 targets PTK6 to inhibit tumorigenic potential and increase drug sensitivity of prostate cancer cells
    Patrice Cagle et al, 2019, Sci Rep CrossRef
  66. Expression of 17β-hydroxysteroid dehydrogenase type 1 in gastric cancer
    Bartosz Adam Frycz et al, 2013, Biomedicine & Pharmacotherapy CrossRef
  67. Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases
    Frank Hilberg et al, 2018, J Pharmacol Exp Ther CrossRef
  68. Genetics of breast cancer bone metastasis: a sequential multistep pattern
    Hassan Fazilaty et al, 2014, Clin Exp Metastasis CrossRef
  69. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
    Martin Schuler et al, 2019, The Lancet Oncology CrossRef
  70. A new screening tool for FGFR inhibitor treatment?
    Aung Naing, 2019, The Lancet Oncology CrossRef
  71. Dovitinib Triggers Apoptosis and Autophagic Cell Death by Targeting SHP-1/p-STAT3 Signaling in Human Breast Cancers
    Yi-Han Chiu et al, 2019, Journal of Oncology CrossRef
  72. Gastric cancer management: Kinases as a target therapy
    Batoul Farran et al, 2017, Clin Exp Pharmacol Physiol CrossRef
  73. Genetics of Pheochromocytomas and Paragangliomas
    Rodrigo Almeida Toledo, 2017, Endocrinology and Metabolism Clinics of North America CrossRef
  74. A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
    Michael Michael et al, 2017, Targ Oncol CrossRef
  75. Targeted and novel therapy in advanced gastric cancer
    Julie H. Selim et al, 2019, Exp Hematol Oncol CrossRef
  76. null
    Michael A. Schumacher et al, 2018 CrossRef
  77. Importance of Translational Research for Targeting Fibroblast Growth Factor Receptor Signaling in Cancer
    null Holzmann et al, 2019, Cells CrossRef
  78. Targeting FGFR in bladder cancer: ready for clinical practice?
    Stijn De Keukeleire et al, 2020, Acta Clin Belg CrossRef
  79. Heart failure as interstitial cancer: emergence of a malignant fibroblast phenotype
    Kelsie E. Oatmen et al, 2019, Nat Rev Cardiol CrossRef
  80. Fibroblast growth factor receptor inhibitors: patent review (2015–2019)
    Giuseppe Marseglia et al, 2019, Expert Opinion on Therapeutic Patents CrossRef
  81. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder
    Robert Roskoski, 2019, Pharmacological Research CrossRef
  82. Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors
    Chiara Casadei et al, 2019, Ther Adv Med Oncol CrossRef
  83. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma
    Fangda Li et al, 2019, Cytokine & Growth Factor Reviews CrossRef
  84. Involvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma
    Ming-Dow Tsay et al, 2019, IJERPH CrossRef
  85. Cancer immunotherapy: Pros, cons and beyond.
    Shuzhen Tan et al, 2020, Biomed Pharmacother CrossRef
  86. Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma
    Tatjana Seitz et al, 2020, Sci Rep CrossRef
  87. The future of bladder cancer therapy: optimizing the inhibition of the fibroblast growth factor receptor
    Rafael Morales-Barrera et al, 2020, Cancer Treatment Reviews CrossRef
  88. The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments
    Sobhani Navid et al, 2020, IJMS CrossRef
  89. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
    Sara Massironi et al, 2020, Cells CrossRef
  90. Trefoil factor family (TFF) peptides and cancer progression
    Shahin Emami et al, 2004, Peptides CrossRef
  91. Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study.
    Jian Ming Xu et al, 2017, Oncotarget CrossRef
  92. Stable Fibroblast Growth Factor 2 Dimers with High Pro-Survival and Mitogenic Potential
    Daria Nawrocka et al, 2020, IJMS CrossRef
  93. Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors
    Qian Qin et al, 2020, Expert Review of Anticancer Therapy CrossRef
  94. Combined CDK4/6 and PD-1 Inhibition in Refractory SMARCA4-Deficient Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
    Elizabeth K. Lee et al, 2020, JCO Precision Oncology CrossRef
  95. Extracellular vesicles from senescent hepatic stellate cells promote cell viability of hepatoma cells through increasing EGF secretion from differentiated THP‑1 cells
    Yuri Miyazoe et al, 2020, biom rep CrossRef
  96. Sialylation of FGFR1 by ST6Gal‑I overexpression contributes to ovarian cancer cell migration and chemoresistance
    Lingling Ou et al, 2020, Mol Med Report CrossRef
  97. Precision medicine for human cancers with Notch signaling dysregulation (Review)
    Masuko Katoh et al, 2019, Int J Mol Med CrossRef
  98. Targeting the FGFR signaling pathway in cholangiocarcinoma: promise or delusion?
    Jing Wang et al, 2020, Ther Adv Med Oncol CrossRef
  99. Effects of Food on the Pharmacokinetic Properties of Surufatinib: A Phase I, Single-dose, Randomized, Open-label Crossover Study in Healthy Subjects
    Hongjie Qian et al, 2020, Clinical Therapeutics CrossRef
  100. Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients
    Ramona Erber et al, 2020, Breast Cancer Res Treat CrossRef
  101. Development of an Immune-Related Risk Signature for Predicting Prognosis in Lung Squamous Cell Carcinoma
    Denggang Fu et al, 2020, Front. Genet. CrossRef
  102. A novel monovalent FGFR1 antagonist: Preclinical safety profiles in rodents and non-human primates
    Ping Yu et al, 2020, Toxicology and Applied Pharmacology CrossRef
  103. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
    Jianming Xu et al, 2020, Lancet Oncol CrossRef
  104. Colitis induced by Lenvatinib in a patient with advanced hepatocellular carcinoma
    Saori Miyajima et al, 2020, Clin J Gastroenterol CrossRef
  105. Targeted Therapy in Metastatic Bladder Cancer: Present Status and Future Directions
    Mathijs Scholtes et al, 2020, Applied Sciences CrossRef
  106. MiR-497 promotes microglia activation and proinflammatory cytokines production in chronic unpredictable stress-induced depression via targeting FGF2
    Xiaoyan Zhai et al, 2020, Journal of Chemical Neuroanatomy CrossRef
  107. Fibroblast Growth Factor Receptor Inhibitors and Nonuremic Calciphylaxis
    Jesse Hirner et al, 2020, JAMA Dermatol CrossRef
  108. Rab8 and Rabin8-Mediated Tumor Formation by Hyperactivated EGFR Signaling via FGFR Signaling.
    Junghwa Choi et al, 2020, Int J Mol Sci CrossRef
  109. A novel prognostic risk score model based on immune-related genes in patients with stage IV colorectal cancer
    Ke Xu et al, 2020 CrossRef
  110. Epithelial Splicing Regulatory Protein (ESPR1) Expression in an Unfavorable Prognostic Factor in Prostate Cancer Patients
    Hyung Ho Lee et al, 2020, Front. Oncol. CrossRef
  111. Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines
    Mario E. Lacouture et al, 2020, The Oncol CrossRef
  112. Blockade of Fgfr1 with PD166866 Protects Cartilage from the Catabolic Effects Induced by Interleukin-1β: A Genome-Wide Expression Profiles Analysis
    Lingxian Yi et al, 2020, CARTILAGE CrossRef
  113. Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures
    T. E. Kähkönen et al, 2020, Cell Oncol. CrossRef
  114. Reversible corneal stromal thinning, acute-onset white cataract and angle-closure glaucoma due to erdafitinib, a fibroblast growth factor receptor inhibitor: Report of three cases
    G. Bauters et al, 2020, Journal Français d'Ophtalmologie CrossRef
  115. Discovery and Optimization of Novel Pyrazole-Benzimidazole CPL304110, as a Potent and Selective Inhibitor of Fibroblast Growth Factor Receptors FGFR (1-3)
    Abdellah Yamani et al, 2020, European Journal of Medicinal Chemistry CrossRef
  116. CSF1R and HCST: Novel Candidate Biomarkers Predicting the Response to Immunotherapy in Non-Small Cell Lung Cancer
    Xiaoguang Qi et al, 2020, Technol Cancer Res Treat CrossRef
  117. Compounds from Natural Sources as Protein Kinase Inhibitors
    Andrea Baier et al, 2020, Biomolecules CrossRef
  118. Nomogram Personalizes and Visualizes the Overall Survival of Patients with Triple-Negative Breast Cancer Based on the Immune Genome
    Peipei Wang et al, 2020, BioMed Research International CrossRef
  119. Clinical Characteristics and Spermatogenesis in Patients with Congenital Hypogonadotropic Hypogonadism Caused by FGFR1 Mutations
    Shuying Li et al, 2020, International Journal of Endocrinology CrossRef
  120. A cyclic peptide retards the proliferation of DU145 prostate cancer cells in vitro and in vivo through inhibition of FGFR2
    Yibo Zhang et al, 2020, MedComm CrossRef
  121. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
    Sangeetha Palakurthi et al, 2019, Cancer Immunol Res CrossRef
  122. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
    Timothy P.S. Perera et al, 2017, Mol Cancer Ther CrossRef
  123. A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.
    Martin H Voss et al, 2019, Clin Cancer Res CrossRef
  124. Promoting Effect of Basic Fibroblast Growth Factor in Synovial Mesenchymal Stem Cell-Based Cartilage Regeneration
    Gensuke Okamura et al, 2020, IJMS CrossRef
  125. The diagnostic and clinicopathological value of Trefoil Factor 3 in patients with gastric cancer: a systematic review and meta-analysis
    Chen-Xing Zhang et al, 2021, Biomarkers CrossRef
  126. Recent advances of dual FGFR inhibitors as a novel therapy for cancer
    Qi Liang et al, 2021, European Journal of Medicinal Chemistry CrossRef
  127. Tumor mutation burden in connection with immune-related survival in uterine corpus endometrial carcinoma
    Ling Zhao et al, 2021, Cancer Cell Int CrossRef
  128. FGFR-TKI resistance in cancer: current status and perspectives
    Sitong Yue et al, 2021, J Hematol Oncol CrossRef
  129. FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
    Silvana Mouron et al, 2021, Breast Cancer Res CrossRef
  130. Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme
    Manali Tilak et al, 2021, IJMS CrossRef
  131. The Effects of Naringenin on miRNA-mRNA Profiles in HepaRG Cells
    Weiyang Fan et al, 2021, IJMS CrossRef
  132. Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
    Guihong Liu et al, 2021, Cell Prolif CrossRef
  133. Surufatinib: First Approval.
    Yahiya Y Syed, 2021, Drugs CrossRef
  134. A functional outside-in signaling network of proteoglycans and matrix molecules regulating autophagy
    Thomas Neill et al, 2021, Matrix Biology CrossRef
  135. Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs
    Maria-Magdalena Georgescu et al, 2021, acta neuropathol commun CrossRef
  136. Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets
    Haijun Wang et al, 2021, Front. Pharmacol. CrossRef
  137. Novel Regulatory Factors and Small-Molecule Inhibitors of FGFR4 in Cancer
    Yanan Liu et al, 2021, Front. Pharmacol. CrossRef
  138. Fibroblasts as immune regulators in infection, inflammation and cancer
    Sarah Davidson et al, 2021, Nat Rev Immunol CrossRef
  139. Activated ERK Signaling Is One of the Major Hub Signals Related to the Acquisition of Radiotherapy-Resistant MDA-MB-231 Breast Cancer Cells.
    Gon-sup Kim, 0 CrossRef
  140. Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer
    Laura Pacini et al, 2021, Cells CrossRef
  141. δ-Catenin Participates in EGF/AKT/p21Waf Signaling and Induces Prostate Cancer Cell Proliferation and Invasion
    Yingjie Shen et al, 2021, IJMS CrossRef
  142. Effects of FGFR Tyrosine Kinase Inhibition in OLN-93 Oligodendrocytes
    Ranjithkumar Rajendran et al, 2021, Cells CrossRef
  143. Clinical Application of Cytokines in Cancer Immunotherapy
    Yi Qiu et al, 2021, DDDT CrossRef
  144. Deciphering the whale's secrets to have a long life
    Francisco Alejandro Lagunas-Rangel, 2021, Experimental Gerontology CrossRef
  145. Oncogenic FGFR Fusions Produce Centrosome and Cilia Defects by Ectopic Signaling
    Alexandru Nita et al, 2021, Cells CrossRef
  146. GZD824 overcomes FGFR1‐V561F/M mutant resistance in vitro and in vivo
    Kaili Jiang et al, 2021, Cancer Med CrossRef
  147. FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
    Anuhya Kommalapati et al, 2021, Cancers CrossRef
  148. Identification of key classification features of early cervical squamous cell carcinoma
    Xiaoxi Wang et al, 2021, Computational Biology and Chemistry CrossRef
  149. Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancer
    Keiko Minashi et al, 2021 CrossRef
  150. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma
    Gentry King et al, 2021, Curr Oncol Rep CrossRef
  151. Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer
    Ikuko Takeda Nakamura et al, 2021, npj Precis. Onc. CrossRef
  152. Development and Characterization of a Novel Peptide—Drug Conjugate with DM1 for Treatment of FGFR2-Positive Tumors
    Yayu Wang et al, 2021, Biomedicines CrossRef
  153. The protein-protein interaction network of intestinal gastric cancer patients reveals hub proteins with potential prognostic value
    Everton Cruz Santos et al, 2021, CBM CrossRef
    Raffaella Maria Gadaleta et al, 2021, Journal of Hepatology CrossRef
  155. Molecular mechanisms of the anti-cancer drug, LY2874455, in overcoming the FGFR4 mutation-based resistance
    Fariba Dehghanian et al, 2021, Sci Rep CrossRef
  156. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
    Richard S. Finn et al, 2021, Clin Cancer Res CrossRef
  157. Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment
    Hye Won Lee et al, 2021, IJMS CrossRef
  158. Identifying Lung Cancer Cell Markers with Machine Learning Methods and Single-Cell RNA-Seq Data
    Guo-Hua Huang et al, 2021, Life CrossRef
  159. Precise editing of FGFR3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma
    Ye Wu et al, 2021, Molecular Therapy CrossRef
  160. Melatonin Suppresses Oral Squamous Cell Carcinomas Migration and Invasion through Blocking FGF19/FGFR 4 Signaling Pathway
    Leilei Wang et al, 2021, IJMS CrossRef
  161. Comprehending Fibroblast Growth Factor Receptor Like 1: Oncogene or Tumor suppressor?
    null Aprajita et al, 2021, Cancer Treatment and Research Communications CrossRef
  162. Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification
    Yanyang Liu et al, 2021, Front. Oncol. CrossRef
  163. Safflower Polysaccharide Inhibits AOM/DSS-Induced Mice Colorectal Cancer Through the Regulation of Macrophage Polarization
    Qun Wang et al, 2021, Front. Pharmacol. CrossRef
  164. Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib
    James Yu et al, 2021, OTT CrossRef
  165. Extracellular vesicles as a new hope for diagnosis and therapeutic intervention for hepatocellular carcinoma
    Natthaphong Nimitrungtawee et al, 2021, Cancer Med CrossRef
  166. Glioma cell-derived FGF20 suppresses macrophage function by activating β-catenin
    Xue Cai et al, 2021, Cellular Signalling CrossRef
  167. FGF10/FGF17 as prognostic and drug response markers in acute myeloid leukemia
    Yanying Ling et al, 2022, Current Research in Translational Medicine CrossRef
  168. Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)
    Liping Hu et al, 2021, European Journal of Medicinal Chemistry CrossRef
  169. Fibroblast growth factor receptor fusions in cancer: opportunities and challenges
    Lingfeng Chen et al, 2021, J Exp Clin Cancer Res CrossRef
  170. The Upregulation of PLXDC2 Correlates with Immune Microenvironment Characteristics and Predicts Prognosis in Gastric Cancer
    Yang Li et al, 2021, Disease Markers CrossRef
  171. Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma
    Naomi Suzuki et al, 2020, Case Rep Gastroenterol CrossRef
  172. Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential
    Claudia Ceci et al, 2022, Pharmacology & Therapeutics CrossRef
  173. Hypocrellin A exerts antitumor effects by inhibiting the FGFR1 signaling pathway in non-small-cell lung cancer
    Lehe Yang et al, 2022, Phytomedicine CrossRef
  174. Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity
    Huey-Jen Lin et al, 2022, Cancers CrossRef
  175. Increased Expression and Altered Cellular Localization of Fibroblast Growth Factor Receptor-Like 1 (FGFRL1) Are Associated with Prostate Cancer Progression
    Lan Yu et al, 2022, Cancers CrossRef
  176. Kinases and therapeutics in pathogen mediated gastric cancer
    Charu Sonkar et al, 2022, Mol Biol Rep CrossRef
  177. Metastatic Immune-Related Genes for Affecting Prognosis and Immune Response in Renal Clear Cell Carcinoma
    Si Sun et al, 2022, Front. Mol. Biosci. CrossRef
  178. Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma
    Zeynep B. Zengin et al, 2022, Urologic Oncology: Seminars and Original Investigations CrossRef
  179. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management.
    Sakti Chakrabarti et al, 2022, Expert Opin Drug Metab Toxicol CrossRef
  180. Pindborg Tumor—An Uncommon Odontogenic Tumor Detected by 68Ga-DOTATOC
    Anna Herden et al, 2022, Diagnostics CrossRef
  181. Fibroblast Growth Factor 19 and Fibroblast Growth Factor 21 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Gastric Bypass
    Jiun-Yu Guo et al, 2022, Nutrients CrossRef
  182. New developments in the biology of fibroblast growth factors
    David M. Ornitz et al, 2022, WIREs Mechanisms of Disease CrossRef
  183. K-Ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications
    Kengo Nakahata et al, 2022 CrossRef
  184. Nephrotoxicity From Molecularly Targeted Chemotherapeutic Agents
    Jaya Kala et al, 2021, Advances in Chronic Kidney Disease CrossRef
  185. Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer
    Chiara Francavilla et al, 2022, Open Biol. CrossRef
  186. Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies
    Robert J. Motzer et al, 2022, Expert Review of Anticancer Therapy CrossRef
  187. null
    Mohini Singh et al, 2022 CrossRef
  188. Metastatic Breast Cancer, Organotropism and Therapeutics: A Review
    Ajaz Ahmad Waza et al, 2021, CCDT CrossRef
  189. In search of inhibitors of anti-cancer drug target Fibroblast Growth Factor Receptors: insights from virtual screening, molecular docking, and molecular dynamics study
    A.M.U.B Mahfuz et al, 2022, Arabian Journal of Chemistry CrossRef
  190. Correlation between amino acid metabolism and self-renewal of cancer stem cells: Perspectives in cancer therapy
    Qi Zhang et al, 2022, WJSC CrossRef
  191. FGFR1 is a potential therapeutic target in neuroblastoma
    Flora Cimmino et al, 2022, Cancer Cell Int CrossRef
  192. FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma
    Mariangela Tamburello et al, 2022, Endocrine CrossRef
  193. A stratification model of hepatocellular carcinoma based on expression profiles of cells in the tumor microenvironment
    Chunting Zeng et al, 2022, BMC Cancer CrossRef
  194. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.
    Hui Liu et al, 2018, Cancer Discov CrossRef
  195. Age‐related decrease in responsiveness of CD271 ‐positive skin stem cells to growth factors
    Hirohiko Akamatsu et al, 2022, Experimental Dermatology CrossRef
  196. Design, synthesis and biological evaluation of a series of novel pyrrolo[2,3-d]pyrimidin/pyrazolo[3,4-d]pyrimidin-4-amine derivatives as FGFRs-dominant multi-target receptor tyrosine kinase inhibitors for the treatment of gastric cancer
    Xiuli Wu et al, 2022, Bioorganic Chemistry CrossRef
  197. Pharmacophore Based Design of Probable FGFR-1 Inhibitors from the 3D Crystal Structure of Infigratinib - A Drug Used in the Treatment of Cholangiocarcinomas
    Koushik Sarker et al, 2022, LDDD CrossRef
  198. Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma
    Menglong Zhang et al, 2022, Disease Markers CrossRef
  199. Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy
    Yun Liu et al, 2022, J Hematol Oncol CrossRef
  200. Vitamin D Derivatives in Acute Myeloid Leukemia: The Matter of Selecting the Right Targets
    Ewa Marcinkowska, 2022, Nutrients CrossRef
  201. Modeling Lung Carcinoids with Zebrafish Tumor Xenograft.
    Michele Caraglia, 0 CrossRef
  202. Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors
    Andliena Tahiri et al, 2022, Oncotarget CrossRef
  203. Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma
    Qi Sun et al, 2022, Cell Death Dis CrossRef
  204. Circ_SNX27 regulates hepatocellular carcinoma development via miR ‐637/ FGFR1 axis
    Hua Li et al, 2022, Environmental Toxicology CrossRef
  205. Overexpressed fibroblast growth factor receptors increase 1,25-dihydroxyvitamin D-dependent differentiation of acute myeloid leukemia cells
    Aleksandra Marchwicka et al, 2022, The Journal of Steroid Biochemistry and Molecular Biology CrossRef
  206. Special issue “The advance of solid tumor research in China”: FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer
    Guanghui Gao et al, 2022, Intl Journal of Cancer CrossRef
  207. Comprehensive analysis of the prognostic value and immune infiltration of FGFR family members in gastric cancer
    Chengcheng Yang et al, 2022, Front. Oncol. CrossRef
  208. A robust Spearman correlation coefficient permutation test
    Han Yu et al, 2022, Communications in Statistics - Theory and Methods CrossRef
  209. Cancer-Associated Fibroblasts: The Origin, Biological Characteristics and Role in Cancer—A Glance on Colorectal Cancer
    Charalampos Fotsitzoudis et al, 2022, Cancers CrossRef
  210. A combined analysis of bulk and single-cell sequencing data reveals that depleted extracellular matrix and enhanced immune processes co-contribute to fluorouracil beneficial responses in gastric cancer
    Shaowei Dong et al, 2022, Front. Immunol. CrossRef
  211. Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
    David J Benjamin et al, 2022, Clin Med Insights Oncol CrossRef
  212. AZD4547 and the Alleviation of Hepatoma Cell Sorafenib Resistance via the Promotion of Autophagy
    Yun Feng et al, 2022, ACAMC CrossRef
  213. Variant Enrichment Analysis to Explore Pathways Disruption in a Necropsy Series of Asbestos-Exposed Shipyard Workers
    Sergio Crovella et al, 2022, IJMS CrossRef
  214. Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion
    Michael H. Storandt et al, 2022, Expert Review of Anticancer Therapy CrossRef
  215. The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors
    Hamidreza Zalpoor et al, 2022, Cell Commun Signal CrossRef
  216. Fibroblast growth factor 2 is a druggable target against glioblastoma: A computational investigation
    Rabeea Siddique et al, 2022, Front. Chem. CrossRef
  217. Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review
    Lei Pan et al, 2023, Front. Immunol. CrossRef
  218. Angiogenesis-related gene signatures reveal the prognosis of cervical cancer based on single cell sequencing and co-expression network analysis
    Jiawen Kang et al, 2023, Front. Cell Dev. Biol. CrossRef
  219. The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma
    Hui Zeng et al, 2023, Front. Immunol. CrossRef
  220. Glycopolymers for Antibacterial and Antiviral Applications
    Ruoyao Mei et al, 2023, Molecules CrossRef
  221. CD8/PD-L1 immunohistochemical reactivity and gene alterations in cutaneous squamous cell carcinoma
    Haruto Nishida et al, 2023, PLoS ONE CrossRef
  222. Basic Fibroblast Growth Factor Blockade Leads to Distinct Cellular Responses in Melanoma B16 Cells
    Zhiyong Wang et al, 2022, Dokl Biochem Biophys CrossRef
  223. Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy
    Xiu-Juan Liu et al, 2023, Bioorganic Chemistry CrossRef
  224. Role of FGFR3 in Bladder Cancer: treatment landscape and future challenges
    Claudia Maria Ascione et al, 2023, Cancer Treatment Reviews CrossRef
  225. Synergetic effect of Azacitidine and Sorafenib in treatment of a case of myeloid neoplasm with sole chromosomal abnormality t(8;22)(p11.2;q11.2)/BCR-FGFR1 rearrangement
    Somprakash Dhangar et al, 2023, Cancer Genetics CrossRef
  226. Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
    Ruiwen Ruan et al, 2023, Mol Cancer CrossRef
  227. The FGF/FGFR signalling mediated anti-cancer drug resistance and therapeutic intervention
    Subhasmita Mahapatra et al, 2023, Journal of Biomolecular Structure and Dynamics CrossRef
  228. Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer
    Anqi Lin et al, 2023, JIR CrossRef
  229. Expression and Purification of FGFR1-Fc Fusion Protein, and its Effects on Human Lung Squamous Carcinoma
    Lulu Zheng et al, 2022, SSRN Journal CrossRef
  230. Important oncogenic and immunogenic roles of SPP1 and CSF1 in hepatocellular carcinoma
    Tianxin Xiang et al, 2023, Med Oncol CrossRef
  231. Expression and Purification of FGFR1-Fc Fusion Protein and Its Effects on Human Lung Squamous Carcinoma
    Lulu Zheng et al, 2023, Appl Biochem Biotechnol CrossRef
  232. Role and mechanistic actions of protein kinase inhibitors as an effective drug target for cancer and COVID
    J. Narayanan et al, 2023, Arch Microbiol CrossRef
  233. Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor
    Maroun Bou Zerdan et al, 2023, Mol Diagn Ther CrossRef
  234. Whole exome and transcriptome analysis revealed the activation of ERK and Akt signaling pathway in canine histiocytic sarcoma
    Hajime Asada et al, 2023, Sci Rep CrossRef
  235. Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1–3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment
    Song Liao et al, 2023, Front. Oncol. CrossRef
  236. Dual-Warhead Conjugate Based on Fibroblast Growth Factor 2 Dimer Loaded with α-Amanitin and Monomethyl Auristatin E Exhibits Superior Cytotoxicity towards Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1
    Daria Nawrocka et al, 2023, IJMS CrossRef
  237. Genomic landscape and expression profile of consensus molecular subtype four of colorectal cancer
    Yujie Lu et al, 2023, Front. Immunol. CrossRef
  238. Identification of novel biomarkers and immune infiltration features of recurrent pregnancy loss by machine learning
    Yujia Luo et al, 2023, Sci Rep CrossRef
  239. Comprehensive analysis of the role of a four-gene signature based on EMT in the prognosis, immunity, and treatment of lung squamous cell carcinoma
    Feng Li et al, 2023, Aging CrossRef
  240. The small molecule fibroblast growth factor receptor inhibitor infigratinib exerts anti‐inflammatory effects and remyelination in a model of multiple sclerosis
    Ranjithkumar Rajendran et al, 2023, British J Pharmacology CrossRef
  241. Receptor Tyrosine Kinase: Still an Interesting Target to Inhibit the Proliferation of Vascular Smooth Muscle Cells
    Yilin Xiong et al, 2023, Am J Cardiovasc Drugs CrossRef
  242. Characterization of the folding and binding properties of the PTB domain of FRS2 with phosphorylated and unphosphorylated ligands
    Valeria Pennacchietti et al, 2023, Archives of Biochemistry and Biophysics CrossRef
  243. The Efficacy and Safety of Surufatinib Combined with Anti PD-1 Antibody Toripalimab in Neoadjuvant Treatment of Locally Advanced Differentiated Thyroid Cancer: A Phase II Study
    Jia-ying Chen et al, 2023, Ann Surg Oncol CrossRef
  244. Targeted Therapies in Advanced Cholangiocarcinoma
    Michael H. Storandt et al, 2023, Life CrossRef
  245. Technological advances define shifting pathway signaling from normal to primary and metastatic colorectal cancer
    Robert G. Ramsay et al, 2023, Growth Factors CrossRef
  246. Regulation of Epithelial-Mesenchymal Transitions by Alternative Splicing: Potential New Area for Cancer Therapeutics
    Ling Li et al, 2023, Genes CrossRef
  247. Virtual screening for novel FGFR2 inhibitors: Exploring Gefitinib-like compounds as promising therapeutic candidates
    Salimat O. Sofela et al, 2023, Informatics in Medicine Unlocked CrossRef
  248. Environment relevant exposure of perfluorooctanoic acid accelerates the growth of hepatocellular carcinoma cells through mammalian target of rapamycin (mTOR) signal pathway
    Jiawei Hong et al, 2023, Environmental Pollution CrossRef
  249. The Role of the Tumor Microenvironment in Triple-Positive Breast Cancer Progression and Therapeutic Resistance
    Qian Pu et al, 2023, Cancers CrossRef
  250. Identification and validation of basic fibroblast growth factor as a prognostic biomarker for the response of lung adenocarcinoma patients to bevacizumab treatment
    Hongtao Jiang et al, 2023, Immunobiology CrossRef
  251. Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy
    Jiangjun Cao et al, 2023, MedComm CrossRef
  252. Synthesis and Evaluation of Novel 99mTc-Labeled FGFR2-Targeting Peptides
    Jingjing Yao et al, 2024, Mol. Pharmaceutics CrossRef
  253. Identification and characterization of CLEC11A and its derived immune signature in gastric cancer
    Qing Zheng et al, 2024, Front. Immunol. CrossRef
  254. Lipopolysaccharide-Educated Cancer-Associated Fibroblasts Facilitate Malignant Progression of Ovarian Cancer Cells via the NF-kB/IL-6/JAK2 Signal Transduction
    Dongjie Wang et al, 2024, Mol Biotechnol CrossRef
  255. Network pharmacology, molecular simulation, and binding free energy calculation-based investigation of Neosetophomone B revealed key targets for the treatment of cancer
    Abbas Khan et al, 2024, Front. Pharmacol. CrossRef
  256. Fibroblast Growth Factor Receptor Inhibitors Decrease Proliferation of Melanoma Cell Lines and Their Activity Is Modulated by Vitamin D
    Anna Piotrowska et al, 2024, IJMS CrossRef
  257. LGALS3BP is a novel and potential biomarker in clear cell renal cell carcinoma
    Lei Li et al, 2024, Aging CrossRef
  258. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
    Masuko Katoh et al, 2024, Nat Rev Clin Oncol CrossRef
  259. Paracrine Regulation and Immune System Pathways in the Inflammatory Tumor Microenvironment of Lung Cancer: Insights into Oncogenesis and Immunotherapeutic Strategies
    Firas Batrash et al, 2024, Cancers CrossRef
  260. Inhibitory Effect of the Ethanolic Seed Extract of Trichosanthes kirilowii on Angiogenesis in Human Umbilical Vein Endothelial Cells
    Shin-Hyung Park et al, 2022, kjopp CrossRef
  261. Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma
    Gaetano Pezzicoli et al, 2024, Medicina CrossRef
  262. Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?
    Erika Stucchi et al, 2024, Expert Opinion on Pharmacotherapy CrossRef
  263. Calcium and Neural Stem Cell Proliferation
    Dafne Astrid Díaz-Piña et al, 2024, IJMS CrossRef
  264. Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology
    Keming Lin et al, 2024, J Transl Med CrossRef
  265. Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression
    Hong Tian et al, 2024, Front. Oncol. CrossRef
  266. Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma
    Heesook Oh et al, 2024, J. Med. Chem. CrossRef
  267. Targeting FGFR for cancer therapy
    Pei Zhang et al, 2024, J Hematol Oncol CrossRef
  268. Effects of triggers of senescence and senolysis in murine pancreatic cancer cells
    Denis Revskij et al, 2024, Hepatobiliary & Pancreatic Diseases International CrossRef